<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diabetic autonomic neuropathy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diabetic autonomic neuropathy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diabetic autonomic neuropathy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher H Gibbons, MD, MMSc, FAAN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic autonomic neuropathy (DAN) is a common form of neuropathy in patients with diabetes mellitus characterized by dysfunction due to impairment of peripheral autonomic nerves. A wide spectrum of manifestations can affect many different organ systems, including the cardiovascular, gastrointestinal, genitourinary, sudomotor and vasomotor, and neuroendocrine systems  (
         <a class="graphic graphic_table graphicRef79376" href="/z/d/graphic/79376.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         This topic will review the clinical manifestations and management of DAN. Other forms of neuropathy associated with diabetes mellitus are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5275.html" rel="external">
          "Epidemiology and classification of diabetic neuropathy"
         </a>
         .)
        </p>
        <p>
         Hereditary sensory and autonomic neuropathies are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6227.html" rel="external">
          "Hereditary sensory and autonomic neuropathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3497208799">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         DAN is a common form of neuropathy in patients with diabetes mellitus. The prevalence of DAN increases with the duration of diabetes. It may be identified in patients at the time of diabetes diagnosis in up to 7 percent [
         <a href="#rid1">
          1
         </a>
         ] but can be as high as 50 percent after 15 years [
         <a href="#rid2">
          2
         </a>
         ]. DAN occurs in patients with type 1 or type 2 diabetes mellitus [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2436859698">
         <span class="h1">
          SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend assessing all patients with diabetes mellitus for DAN. Some patients with DAN may not have overt symptoms. Early recognition of clinical or subclinical DAN is useful for risk stratification and to guide specific glycemic, lipid, and blood pressure targets. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         We screen for DAN at the time of diagnosis of type 2 diabetes and five years after the diagnosis of type 1 diabetes, in agreement with guidelines from the American Diabetes Association [
         <a href="#rid4">
          4
         </a>
         ]. Screening should include a history and physical examination to assess for symptoms and signs of autonomic dysfunction. Symptoms can include orthostatic dizziness, palpitations, syncope, bloating or early satiety, and/or chronically dry skin. Signs of autonomic neuropathy can include orthostatic hypotension, resting tachycardia, or evidence of dry and cracked skin [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         If screening is positive, directed testing may be performed to help establish the diagnosis of DAN. (See
         <a class="local">
          'Cardiovascular autonomic neuropathy'
         </a>
         below and
         <a class="local">
          'Peripheral sudomotor and vasomotor neuropathy'
         </a>
         below and
         <a class="local">
          'Gastrointestinal autonomic neuropathy'
         </a>
         below and
         <a class="local">
          'Genitourinary autonomic neuropathy'
         </a>
         below.)
        </p>
        <p>
         If initial screening is negative, a history and physical examination for symptoms and signs of autonomic dysfunction should be repeated annually.
        </p>
        <p class="headingAnchor" id="H2396156604">
         <span class="h1">
          OVERVIEW OF MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         DAN represents a complication of diabetes mellitus. Management to help prevent development or progression of DAN involves optimizing glycemic control, treating comorbid vascular risk factors (eg, hypertension, hyperlipidemia, obesity), and addressing specific autonomic symptoms to provide symptomatic relief and reduce associated morbidity.
        </p>
        <p class="headingAnchor" id="H793183569">
         <span class="h2">
          Glycemic control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glycemic control is a key component of the overall management strategy to help prevent and to slow progression of DAN.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycemic targets
         </strong>
         – The appropriate glycated hemoglobin A1C target for patients with diabetes mellitus (with or without DAN) includes balancing individual benefits of improved glycemic control to reduce risk of complications with risks of treatment-related complications (eg, hypoglycemia, weight gain).
         <em>
         </em>
         These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">
          "Glycemic control and vascular complications in type 1 diabetes mellitus", section on 'Glycemic targets'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">
          "Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rate of glycemic improvement
         </strong>
         – For individuals with chronic hyperglycemia, our practice is to achieve a target hemoglobin A1C gradually, not exceeding a 3-point change in hemoglobin A1C in three months. Extremely rapid improvements in glycemic control in patients with chronic hyperglycemia may be associated with the development of microvascular complications of diabetes, including DAN and peripheral neuropathy [
         <a href="#rid6">
          6
         </a>
         ]. This phenomenon is called treatment-induced neuropathy of diabetes (TIND). (See
         <a class="medical medical_review" href="/z/d/html/5275.html" rel="external">
          "Epidemiology and classification of diabetic neuropathy", section on 'Treatment-induced neuropathy of diabetes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TIND appears to be more common in those with type 1 diabetes, most likely because of the rapid change in glycemic control that can occur with the use of insulin. Based on the limited data available, chronic hyperglycemia of a year or more may be necessary prior to an abrupt decrease in average glucose levels to result in neuropathy development [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Not all experts are convinced that overly rapid glycemic control or reduction in hemoglobin A1C can cause neuropathy. An alternative explanation for this finding is that the worsening of neuropathy is an epiphenomenon associated with but not caused by overly rapid glycemic control. The prevalence is unknown and data supporting TIND come from uncontrolled and retrospective studies. No evidence of TIND was observed in data from prospective controlled trials such as the Diabetes Control and Complications Trial (DCCT). However, "early worsening retinopathy" was noted within the DCCT trial, a phenomenon also seen in individuals with TIND [
         <a href="#rid8">
          8-11
         </a>
         ]. The parallel development of retinopathy and neuropathy in acute glycemic control suggests an inflammatory microvascular process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence of efficacy
         </strong>
         – Intensive therapy with insulin in subjects with type 1 diabetes was found to reduce the incidence of cardiovascular autonomic neuropathy (CAN) by 53 percent in the DCCT [
         <a href="#rid12">
          12
         </a>
         ], and the benefit of prior intensive therapy was found to persist for up to 14 years in these subjects [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The potential efficacy of intensive therapy in patients with type 2 diabetes and microalbuminuria was examined in the Steno type 2 trial [
         <a href="#rid14">
          14
         </a>
         ]. In this prospective open-label trial, 160 patients were assigned to standard or intensive therapy. The intensive regimen consisted of both behavioral therapy (including advice concerning diet, exercise, and smoking cessation) and pharmacologic intervention (consisting of the administration of multiple agents to attain several aggressive therapeutic goals)  (
         <a class="graphic graphic_table graphicRef69810" href="/z/d/graphic/69810.html" rel="external">
          table 2
         </a>
         ). At a mean follow-up of 7.8 years, progression to autonomic neuropathy occurred in 24 patients assigned to the intensive regimen compared with 43 patients assigned to standard therapy (30 versus 54 percent, relative risk [RR] 0.37, 95% CI 0.18-0.79). This benefit was sustained at a mean of 13.3 years (the trial intervention period plus an additional 5.5 years of observational follow-up) [
         <a href="#rid15">
          15
         </a>
         ].
         <em>
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Multifactorial risk factor reduction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, a cautionary note comes from the results of the ACCORD trial, in which intensive glycemic control was linked to increased mortality in type 2 diabetes [
         <a href="#rid16">
          16
         </a>
         ]. The design of the ACCORD trial limited the ability to determine whether the differences in glycemia between the treatment groups or the different profile of the many medications utilized to achieve the glycemic levels was responsible for the excess mortality.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2016798990">
         <span class="h2">
          Risk factor management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Modifiable risk factors in addition to hyperglycemia include hypertension, hyperlipidemia, and smoking. Multimodal management of vascular risk factors reduces cardiovascular mortality in patients with diabetes [
         <a href="#rid15">
          15,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Multifactorial risk factor reduction'
         </a>
         .)
        </p>
        <p>
         Vascular risk factor management can also reduce the incidence and may help reduce the progression of diabetic neuropathy, including DAN [
         <a href="#rid18">
          18-20
         </a>
         ]. In a prospective, observational study of 1172 patients with type 1 diabetes followed for a mean of 7.3 years, the rate of development of diabetic neuropathy was 24 percent [
         <a href="#rid18">
          18
         </a>
         ]. After adjustment for glycated hemoglobin levels and duration of diabetes, other risk factors associated with the incidence of diabetic neuropathy included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of cardiovascular disease (odds ratio [OR] 2.7, 95% CI 1.7-4.5)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension (OR 1.9, 95% CI 1.3-2.8)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of smoking (OR 1.6, 95% CI 1.2-2.0)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Body-mass index (OR 1.4, 95% CI 1.2-1.6)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triglycerides (OR 1.4, 95% CI 1.2-1.6)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total cholesterol (OR 1.3, 95% CI 1.1-1.5)
        </p>
        <p>
        </p>
        <p>
         While poor glucose control and vascular risk factors appear to be associated with the development of diabetic neuropathy, the effects of these risk factors on DAN progression are less clear and, other than the beneficial effects of glycemic control in type 1 diabetes, high-quality evidence is sparse.
        </p>
        <p>
         In addition to management of modifiable comorbid conditions, certain medications may cause or worsen neuropathy. These medications should be discontinued if possible  (
         <a class="graphic graphic_table graphicRef69751" href="/z/d/graphic/69751.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3403700866">
         <span class="h2">
          Symptomatic treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         DAN may be detected in the majority of patients with diabetes with neurophysiologic testing but is classified as subclinical or clinical depending upon the presence or absence of symptoms [
         <a href="#rid21">
          21
         </a>
         ]. Symptoms commonly involve the cardiovascular system, but other symptoms involving vasomotor, gastrointestinal, and genitourinary systems may also occur. Specific manifestations and respective management strategies are discussed below.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CARDIOVASCULAR AUTONOMIC NEUROPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular autonomic neuropathy (CAN) is defined as the impairment of autonomic control of the cardiovascular system [
         <a href="#rid22">
          22
         </a>
         ]. It may be associated with several abnormalities in cardiovascular function.
        </p>
        <p>
         The prevalence of CAN varies considerably, which reflects variability in the sensitivity of diagnostic tests used, diagnostic criteria, and the population studied. In the longitudinal Screen-Detected Diabetes in Primary Care (ADDITION) study that included 443 patients with type 2 diabetes followed for a median of 13 years, the annual incidence of CAN was 1.8 percent in individuals with well-controlled diabetes [
         <a href="#rid23">
          23
         </a>
         ]. This incidence is lower than in other reports, which may reflect improvements in early detection and risk factor reduction.
        </p>
        <p class="headingAnchor" id="H2095504945">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAN may be associated with overt clinical symptoms such as palpitations at rest, exercise intolerance, orthostatic hypotension, syncope, intraoperative cardiovascular instability, and silent myocardial infarction and ischemia [
         <a href="#rid24">
          24
         </a>
         ]. In addition, CAN may be identified by cardiovascular reflex testing performed on screening evaluation of asymptomatic individuals.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Resting tachycardia and exercise intolerance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The earliest clinical manifestation of CAN may be a resting tachycardia. The increased resting heart rate is due to unopposed cardiac sympathetic nerve activity.
        </p>
        <p>
         Exercise intolerance is usually due to impaired augmentation of cardiac output resulting from inadequate sympathetic modulation. Persistent sinus tachycardia can occur and may be associated with minimal or absent variation in heart rate during activities that normally increase heart rate variability, such as deep breathing and the Valsalva maneuver.
        </p>
        <p>
         As autonomic neuropathy progresses, the resting heart rate gradually slows [
         <a href="#rid25">
          25
         </a>
         ]. Cardiac denervation can occur in diabetic patients with advanced autonomic neuropathy. It is characterized by a fixed heart rate, in the range of 80 to 90 beats per minute, and is associated with an elevated risk of painless myocardial infarction, arrhythmias, and sudden death [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="local">
          'Adverse cardiovascular events'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2892989401">
         <span class="h3">
          Orthostatic (postural) symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical features of CAN may be related to posture, provoked by standing and relieved by sitting. Tachycardia or hypotension may occur, causing palpitations, lightheadedness, dizziness, or syncope.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postural tachycardia
         </strong>
         — A posture-induced tachycardia without a fall in blood pressure can result in significant postural symptoms of lightheadedness, dizziness, and presyncope. Postural tachycardia is typically seen in patients with diabetes who have a high resting heart rate due to vagal cardiac neuropathy with an unopposed cardiac sympathetic nerve activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although postural tachycardia may occur both with diabetes and postural tachycardia syndrome (POTS), patients with postural tachycardia and diabetes should be diagnosed with DAN. While both conditions can be due to an underlying neuropathy, treatments may differ, and the role of glycemic control and vascular risk factor management is an additional component of the treatment of DAN. (See
         <a class="local">
          'Overview of management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The clinical features and management of POTS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5100.html" rel="external">
          "Postural tachycardia syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Orthostatic hypotension
         </strong>
         — Orthostatic hypotension is defined as a fall in blood pressure of ≥20 mmHg systolic or ≥10 mmHg diastolic following a change from a supine to a standing (or upright tilt table test) position [
         <a href="#rid27">
          27
         </a>
         ]. Orthostatic hypotension results from a combination of central and peripheral cardiovascular sympathetic denervation. It reflects failure of vasoconstriction in both the splanchnic and peripheral vascular beds.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Symptoms and presentations may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intermittent dizziness
         </strong>
         – Dizziness or lightheadedness may occur spontaneously or may be provoked by dehydration. Symptoms are typically intermittent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Day-to-day variability of symptoms may also be provoked by insulin therapy, which has provoked hypotension in both diabetic [
         <a href="#rid28">
          28
         </a>
         ] and nondiabetic [
         <a href="#rid29">
          29
         </a>
         ] patients with autonomic failure, although the clinical relevance of this to most patients with diabetes is not known.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Supine hypertension
         </strong>
         – A loss of the diurnal variation in blood pressure may lead to supine hypertension occurring at night [
         <a href="#rid30">
          30
         </a>
         ]. This may also occur to a lesser degree in diabetic patients without neuropathy. In addition, ambulatory 24-hour blood pressure monitoring has detected hypertension in over 50 percent of subjects with type 2 diabetes and CAN, despite normal office blood pressure measurements [
         <a href="#rid31">
          31
         </a>
         ]. Medications used to treat orthostatic hypotension may also cause supine hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Postprandial hypotension
         </strong>
         – Supine and standing systolic blood pressures may fall profoundly after meals [
         <a href="#rid32">
          32
         </a>
         ]. The mechanism of postprandial hypotension in DAN is unclear. Both inadequate sympathetic compensation to meal-induced pooling of blood in the splanchnic circulation and vasodilatory gut peptides may contribute to this phenomenon [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Syncope
         </strong>
         – In its most severe form, orthostatic hypotension can cause significant drops in blood pressure resulting in syncope. This severe form of orthostasis is rare, with most patients having milder symptoms that are amenable to therapeutic interventions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Retrospective data suggest that the presence of orthostatic hypotension is associated with microvascular and macrovascular complications of diabetes [
         <a href="#rid35">
          35
         </a>
         ]. The presence of orthostatic hypotension in diabetes is associated with a significant increase in 10-year mortality [
         <a href="#rid36">
          36,37
         </a>
         ]. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Adverse cardiovascular events
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of CAN is associated with the risk of silent myocardial ischemia. A meta-analysis of 12 cross-sectional studies found that patients with CAN had a higher frequency of silent myocardial ischemia than patients without CAN (pooled prevalence rate ratio 1.96, 95% CI 1.53-2.51) [
         <a href="#rid21">
          21
         </a>
         ]. In a study of 522 patients with type 2 diabetes and no known or suspected coronary artery disease who underwent adenosine stress radionuclide myocardial perfusion imaging studies, silent ischemia was detected in 113 (22 percent) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The mechanisms of silent myocardial ischemia are complex and not completely understood. This issue is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1488.html" rel="external">
          "Silent myocardial ischemia: Epidemiology, diagnosis, treatment, and prognosis", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         CAN is also associated with other adverse cardiac outcomes such as cardiac arrhythmia, heart failure, and need for coronary revascularization. A study of 120 patients with type 1 or type 2 diabetes and no history of myocardial infarction or angina but at least two additional cardiovascular risk factors followed for an average of 4.5 years found that a major cardiac event was significantly more common in patients with CAN than in those without CAN (24 versus 7 percent) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         CAN is also associated with an increased mortality risk. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Other vascular complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of CAN may also be associated with kidney disease and cerebrovascular events.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney disease
         </strong>
         – CAN has been associated with the development of chronic kidney disease. In a prospective study of subjects with type 1 diabetes who were followed for over 14 years, CAN and abnormal orthostatic diastolic blood pressure were associated with the subsequent development of kidney complications [
         <a href="#rid40">
          40
         </a>
         ]. In another study including 1523 subjects with diabetes followed for 16 years, both a higher resting heart rate and a lower heart rate variability were associated with an increased risk of developing end-stage kidney disease [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebrovascular disease
         </strong>
         – CAN may be associated with an increased stroke risk. In patients with type 2 diabetes enrolled in the longitudinal Appropriate Blood Pressure Control in Diabetes trial, CAN was an independent risk factor for the occurrence of stroke [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Diagnostic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAN may be diagnosed with cardiovascular reflex testing in both symptomatic patients and asymptomatic patients. Tests of autonomic function may include assessment of heart rate (for resting tachycardia), heart rate variability (including the expiration-to-inspiration ratio), response to the Valsalva maneuver, and assessment of orthostatic hypotension.
        </p>
        <p>
         Some experts believe that a confident diagnosis of CAN requires abnormalities in two or more cardiac autonomic functions [
         <a href="#rid21">
          21,43
         </a>
         ]. This notion underlies proposed criteria for the diagnosis and staging of CAN [
         <a href="#rid22">
          22,44
         </a>
         ], which specify:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Possible or early CAN – one abnormal cardiovascular reflex test [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Definite or confirmed CAN – two abnormal cardiovascular reflex tests [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe or advanced CAN – definite CAN and the additional presence of orthostatic hypotension [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There is no evidence that any one test has diagnostic superiority [
         <a href="#rid22">
          22,44,48
         </a>
         ], although it is rare that a single test would be administered.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common diagnostic test options
         </strong>
         – The selection of specific autonomic tests  (
         <a class="graphic graphic_table graphicRef66386" href="/z/d/graphic/66386.html" rel="external">
          table 4
         </a>
         ) varies according to local protocols and availability but typically includes measures that assess several different components of the autonomic reflex arc [
         <a href="#rid49">
          49
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Parasympathetic function (eg, heart rate response to Valsalva maneuver)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sympathetic adrenergic function (eg, blood pressure change to standing)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sympathetic cholinergic function (eg, quantitative sudomotor axon reflex testing)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Investigational tests
         </strong>
         – Other tests using radiolabeled analogues of norepinephrine can provide direct assessments of the pattern of cardiac sympathetic innervation and help establish the diagnosis of CAN. However, these have limited clinical utility because they are expensive and not widely available. These include [
         <a href="#rid50">
          50-53
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         123-I-metaiodobenzylguanidine (MIBG; iobenguane I-123)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         11-C-hydroxyephedrine scintigraphy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Scintigraphy has a greater sensitivity to detect more subtle degrees of CAN than is possible by (indirect) cardiovascular reflex testing. Conventional measures of autonomic function use indirect methods relying on cardiovascular reflexes, which can detect early abnormalities in parasympathetic integrity but are relatively insensitive to sympathetic adrenergic deficits [
         <a href="#rid54">
          54
         </a>
         ]. Among patients with type 1 diabetes and no evidence of DAN on cardiovascular reflex testing, abnormalities in cardiac innervation by cardiac MIBG scanning have been noted in some small studies [
         <a href="#rid50">
          50,52
         </a>
         ]. In addition, 11-C-hydroxyephedrine scintography facilitates the quantitative regional characterization of sympathetic neuronal dysfunction and loss [
         <a href="#rid55">
          55
         </a>
         ]. It undergoes highly specific uptake and retention in sympathetic nerve terminals [
         <a href="#rid56">
          56,57
         </a>
         ] and, in comparison with MIBG, the images are less affected by nonneuronal uptake [
         <a href="#rid58">
          58
         </a>
         ] and tissue attenuation [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of CAN involves glycemic control and risk factor reduction in an attempt to reduce disease progression and associated morbidity as well as symptomatic strategies to alleviate symptoms. Symptomatic therapy is administered in a step-wise fashion, to minimize adverse treatment effects.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General treatment measures for all patients
         </strong>
         – Glycemic control and risk factor management strategies for all patients with CAN should also incorporate interventions to increase overall cardiovascular fitness and weight control since there is evidence that an exercise program can improve surrogate measures of both early and more advanced CAN [
         <a href="#rid60">
          60,61
         </a>
         ]. In individuals with type 2 diabetes, there is a beneficial effect of weight loss on autonomic function, although it is unclear if this translates into a clinically meaningful outcome [
         <a href="#rid62">
          62
         </a>
         ]. However, the clinical benefits of weight loss across all functional outcomes in type 2 diabetes support this clinical recommendation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonpharmacologic symptomatic treatment
         </strong>
         – The initial step in managing CAN symptoms involves several nonpharmacologic strategies that are used for patients with orthostatic hypotension. For some patients with mild symptoms, these measures may be sufficient to achieve symptom control without pharmacologic interventions. Strategies include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Detailed review and removal of any medications that may worsen orthostatic hypotension  (
         <a class="graphic graphic_table graphicRef130809" href="/z/d/graphic/130809.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increase in fluid intake and liberalize salt intake.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Modify daily activities (eg, stand upright slowly, elevate head of bed, flex hands and/or feet before standing).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, we typically
         <strong>
          avoid
         </strong>
         measures aimed at increasing peripheral vascular tone (such as body stockings and gravity suits) that may be used for other patients with orthostatic hypotension. They often prove ineffective for patients with CAN since blood pooling probably occurs in the large splanchnic vascular bed [
         <a href="#rid63">
          63
         </a>
         ]. Furthermore, in individuals with diabetic peripheral neuropathy, pressure sores can occur with compression stockings and should be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nonpharmacologic measures for patients with orthostatic hypotension are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">
          "Treatment of orthostatic and postprandial hypotension", section on 'Nonpharmacologic measures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacologic symptomatic treatment
         </strong>
         – For patients with CAN whose symptoms do not resolve with nonpharmacologic treatment options, medications used for treatment of orthostatic hypotension may provide additional relief. The selection of agent depends on symptom severity and patient risk factors. Options for patients with CAN include  (
         <a class="graphic graphic_table graphicRef130807" href="/z/d/graphic/130807.html" rel="external">
          table 6
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">
          Fludrocortisone
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">
          Midodrine
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="93840" href="/z/d/drug information/93840.html" rel="external">
          Droxidopa
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We typically do
         <strong>
          not
         </strong>
         use norepinephrine transporter (NET) inhibitors for patients with CAN as these agents generally require intact peripheral sympathetic functioning.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The approach to the pharmacologic treatment of orthostatic hypotension is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">
          "Treatment of orthostatic and postprandial hypotension", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of supine hypertension
         </strong>
         – Supine hypertension is a common manifestation of CAN. It may reflect an imbalance in sympathetic and parasympathetic tone. Supine hypertension may accompany and be a treatment-limiting factor for patients with concomitant orthostatic hypotension. Management is challenging, and the approach is primarily guided by indirect evidence, clinical experience, and expert consensus [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The management of supine hypertension is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">
          "Treatment of orthostatic and postprandial hypotension", section on 'Supine hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          PERIPHERAL SUDOMOTOR AND VASOMOTOR NEUROPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The peripheral sympathetic cholinergic system controls sweat function and thermoregulation. The relationship between peripheral autonomic denervation and its effects on the peripheral vasculature was recognized as early as 1941 when it was noted that diabetic patients with neuropathy had similar peripheral vasomotor reflexes as nondiabetic patients after sympathectomy [
         <a href="#rid65">
          65
         </a>
         ]. This loss of sympathetic vascular innervation results in high peripheral blood flow through arteriovenous shunting and abnormal local reflex vascular control [
         <a href="#rid24">
          24
         </a>
         ]. Sudomotor and vasomotor neuropathies are common in patients with diabetes mellitus and typically are comorbid complications of diabetic axonal polyneuropathies. (See
         <a class="medical medical_review" href="/z/d/html/5275.html" rel="external">
          "Epidemiology and classification of diabetic neuropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1549343263">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Loss of sudomotor function leads to thermoregulatory impairment and hyperthermia. Loss of sweat function occurs distally in a stocking-and-glove distribution and leads to a compensatory proximal hyperhidrosis [
         <a href="#rid66">
          66
         </a>
         ]. Sudomotor and vasomotor dysfunction may also cause changes in the texture of the skin and/or underlying tissue and joints.
        </p>
        <p>
         Common features of peripheral autonomic neuropathy include [
         <a href="#rid22">
          22,66-68
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proximal hyperhidrosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acral symptoms (hyperthermia, pruritus, aching, cramping)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin changes (dry skin, venous prominence, callus formation, loss of nails)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral edema, associated with foot ulceration and/or poor wound healing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroarthropathy (Charcot arthropathy)  (
         <a class="graphic graphic_picture graphicRef67753" href="/z/d/graphic/67753.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Neuroarthropathy can lead to spontaneous fractures followed by progressive bone disorganization with an increased risk of secondary ulceration. (See
         <a class="medical medical_review" href="/z/d/html/5608.html" rel="external">
          "Diabetic neuroarthropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Diagnostic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of peripheral autonomic neuropathy may be confirmed with superficial recording modalities that identify sudomotor or vasomotor dysfunction after chemical or electrical stimulation. These include the following techniques:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Quantitative sudomotor axon reflex testing (QSART) can be used for the detection of early peripheral sympathetic denervation [
         <a href="#rid69">
          69
         </a>
         ]. QSART involves measuring sweat output both at baseline and following a mild electrical stimulation used to stimulate sweat.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Galvanic skin response, also referred to as the sympathetic skin response, offers a surrogate measure of sympathetic innervation in the hands and feet [
         <a href="#rid70">
          70
         </a>
         ]. This sympathetic skin response involves measuring changes in skin conductivity due to sweat output. However, it can be an unreliable measure of sudomotor function and is frequently absent in the older population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measurement of vascular responses in the foot is an alternative method to detect peripheral sympathetic denervation. Thermal-induced vasoconstriction (rather than the normal vasodilation) reflects vascular denervation and is present only in those patients with both autonomic and somatic neuropathy [
         <a href="#rid71">
          71
         </a>
         ]. Impairment of local axon reflex dilatation is thought to reflect depletion of local vasoactive neuropeptides.
        </p>
        <p>
        </p>
        <p>
         Peripheral autonomic dysfunction may also be identified during routine nerve conduction studies. Motor nerve conduction velocity is decreased in patients with other evidence of small fiber damage, particularly loss of thermal sensation. However, peripheral autonomic neuropathy correlates poorly with motor nerve dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">
          "Overview of nerve conduction studies", section on 'Motor nerve conduction'
         </a>
         .)
        </p>
        <p>
         Skin biopsy assessment is sometimes used to detect autonomic (small fiber) neuropathy [
         <a href="#rid72">
          72
         </a>
         ]. In addition, the assessment of sweat gland nerve fiber density has been studied as a marker of sudomotor neuropathy [
         <a href="#rid73">
          73,74
         </a>
         ]. However, the diagnostic sensitivity of intraepidermal nerve fiber assessment is suboptimal so its clinical role for the quantitation of DAN remains unclear [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14144.html" rel="external">
          "Skin biopsy for the evaluation of peripheral nerve disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of peripheral sudomotor and vasomotor neuropathy is generally supportive. Lifestyle modifications such as cooling garments and avoidance of warm environments can improve symptoms. Clinicians should
         <strong>
          avoid
         </strong>
         the temptation to treat a proximal compensatory hyperhidrosis because treatment increases the risk of hyperthermia.
        </p>
        <p>
         Comprehensive foot examination is warranted to optimize foot care and prevent foot infection and/or ulceration. (See
         <a class="medical medical_review" href="/z/d/html/1749.html" rel="external">
          "Evaluation of the diabetic foot"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          GASTROINTESTINAL AUTONOMIC NEUROPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         DAN that involves autonomic fibers of the enteric nervous system may cause upper and lower gastrointestinal symptoms. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastroesophageal reflux disease (GERD)
         </strong>
         – The most common symptoms of GERD are heartburn (pyrosis) and regurgitation. Other extraesophageal manifestations of GERD include bronchospasm, laryngitis, and chronic cough. Dysphagia for liquids and/or solids is rarely seen in diabetes mellitus. (See
         <a class="medical medical_review" href="/z/d/html/2643.html" rel="external">
          "Diabetic autonomic neuropathy of the gastrointestinal tract", section on 'Gastroesophageal reflux disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastroparesis
         </strong>
         – Symptoms of gastroparesis include nausea, vomiting, early satiety, bloating, and/or upper abdominal pain. Patients with diabetic gastroparesis may also present with symptoms that are not directly related to the gastroparesis but are due to complications of poor glycemic control. Gastroparesis may improve with stable glycemic control. (See
         <a class="medical medical_review" href="/z/d/html/2643.html" rel="external">
          "Diabetic autonomic neuropathy of the gastrointestinal tract", section on 'Gastroparesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diarrhea
         </strong>
         – Diarrhea, and rarely steatorrhea, can occur in patients with DAN, particularly those with advanced disease. The diarrhea is watery and painless, occurs at night, and may be associated with fecal incontinence. Bouts of diarrhea can be episodic with intermittent, normal bowel habits or even alternating with periods of constipation. (See
         <a class="medical medical_review" href="/z/d/html/2643.html" rel="external">
          "Diabetic autonomic neuropathy of the gastrointestinal tract", section on 'Diabetic diarrhea'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The clinical features, diagnosis, and treatment of gastrointestinal complications of DAN are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2643.html" rel="external">
          "Diabetic autonomic neuropathy of the gastrointestinal tract"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          GENITOURINARY AUTONOMIC NEUROPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic genitourinary autonomic neuropathy is responsible for several syndromes including bladder dysfunction, retrograde ejaculation, erectile dysfunction, and dyspareunia (due to decreased vaginal lubrication) [
         <a href="#rid76">
          76
         </a>
         ]. Symptoms may be present in up to 50 percent of individuals with diabetes mellitus [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2915893354">
         <span class="h2">
          Bladder dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic bladder dysfunction initially presents as a decrease in the ability to sense a full bladder from impaired afferent innervation [
         <a href="#rid78">
          78
         </a>
         ]. Subsequent efferent impairment leads to incomplete emptying. These abnormalities can result in overflow incontinence, poor urinary stream, and recurrent urinary tract infections. Lower urinary tract symptoms (frequency, urgency, nocturia) were present in approximately 20 percent of males with type 1 diabetes at the 10-year follow-up time point after completion of the Diabetes Control and Complications Trial (DCCT) [
         <a href="#rid79">
          79
         </a>
         ] while urinary incontinence was reported in 38 percent of females [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         The management of chronic urinary incontinence is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6881.html" rel="external">
          "Female urinary incontinence: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14611.html" rel="external">
          "Urinary incontinence in men", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H327496326">
         <span class="h2">
          Sexual dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sexual dysfunction due to autonomic neuropathy may cause several symptoms. However, the evidence for diabetes as an independent risk factor for sexual dysfunction is limited; depression and anxiety may be more important predictors of sexual dysfunction [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Male sexual dysfunction
         </strong>
         – Erectile dysfunction is a common manifestation of DAN and may be associated with the risk of cardiovascular disease [
         <a href="#rid83">
          83
         </a>
         ]. Retrograde ejaculation reflects loss of coordinated internal urethral sphincter closure with external urethral sphincter relaxation during ejaculation. It may be manifest as cloudy urine postcoitally due to the presence of sperm. Impotence due to autonomic neuropathy usually occurs as a severe manifestation along with other features of somatic or autonomic neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evaluation and treatment of male sexual dysfunction is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7468.html" rel="external">
          "Evaluation of male sexual dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">
          "Treatment of male sexual dysfunction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Female sexual dysfunction
         </strong>
         – Genitourinary neuropathy may cause vulvovaginal symptoms, including dryness, dyspareunia, and bleeding. Sexual dysfunction is more common in females with diabetes compared with those without diabetes [
         <a href="#rid81">
          81,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evaluation and management of female sexual dysfunction is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5424.html" rel="external">
          "Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5485.html" rel="external">
          "Overview of sexual dysfunction in females: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          OTHER MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other symptoms that may occur with DAN include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Difficulty with night driving
         </strong>
         – Dysfunction in pupillary constrictor muscles may result in failure in dark adaptation [
         <a href="#rid85">
          85
         </a>
         ]. Patients may report difficulty with dark vision or adapting to headlights of facing traffic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoglycemic episodes
         </strong>
         – Alterations in neuroendocrine responses attributed to DAN include a reduction in glucagon and epinephrine secretion in response to hypoglycemia, thereby increasing the likelihood of hypoglycemic episodes, also referred to as hypoglycemia-associated autonomic failure [
         <a href="#rid86">
          86-88
         </a>
         ]. In subjects with DAN, decreased counterregulatory catecholamine responses may increase the risk for severe hypoglycemia [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">
          "Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus", section on 'Hypoglycemia-associated autonomic failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, patients with DAN may also have an impaired awareness of hypoglycemia, perhaps related to impaired peripheral nerve signaling [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">
          "Hypoglycemia in adults with diabetes mellitus", section on 'Impaired awareness of hypoglycemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3378102076">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2800328137">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Longitudinal studies of patients with DAN have typically reported five-year mortality rates ranging between 16 and 53 percent [
         <a href="#rid91">
          91-95
         </a>
         ]. Although the majority of deaths result from associated cardiovascular disease, cardiorespiratory arrest secondary to autonomic denervation has been implicated in some patients [
         <a href="#rid95">
          95,96
         </a>
         ]. Two meta-analyses of diabetic patients have found that cardiovascular autonomic neuropathy (CAN) is associated with an increased risk of mortality [
         <a href="#rid43">
          43,97
         </a>
         ]. In one meta-analysis, the mortality of autonomic neuropathy-free subjects over 5.5 years was approximately 5 percent, but this increased to 27 percent with the onset of abnormal cardiovascular reflex tests [
         <a href="#rid97">
          97
         </a>
         ]. In a subsequent meta-analysis, the magnitude of the association was stronger for studies that required more than one abnormality of cardiovascular function to define CAN [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         There are several potential mechanisms by which DAN may increase mortality rates:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diminished perception of cardiac ischemia among patients with diabetes [
         <a href="#rid98">
          98-100
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired cardiovascular response to physiologic stressors such as surgery or infection [
         <a href="#rid101">
          101,102
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arrhythmogenicity due to alterations in vagal control of heart rhythm or QT interval [
         <a href="#rid103">
          103,104
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Denervated myocardial tissue that has focal areas of reinnervation at increased risk for arrhythmia [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Studies reporting the highest mortality rates have typically enrolled symptomatic patients with abnormalities of both the sympathetic and parasympathetic divisions of the autonomic nervous system. Postural hypotension appears to predict a poor prognosis [
         <a href="#rid35">
          35,94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3724771421">
         <span class="h2">
          Role of comorbid risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the increased risk of cardiac morbidity and mortality from DAN, other conditions also contribute to the mortality risk associated with DAN.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atherosclerotic heart disease
         </strong>
         – DAN is associated with an elevated risk of developing atherosclerotic heart disease. In the Rochester Diabetic Neuropathy Study (RDNS), a prospective, longitudinal, population-based study, 21 cases of sudden cardiac death occurred in 462 patients with diabetes who were followed for over 15 years [
         <a href="#rid106">
          106
         </a>
         ]. All 21 with sudden cardiac death had evidence of preceding severe atherosclerosis and myocardial damage. Autonomic dysfunction was not associated with sudden cardiac death after adjusting for electrocardiogram abnormalities and stage of nephropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic kidney disease
         </strong>
         – In a prospective observational study that followed patients with type 1 diabetes who had nephropathy (n = 197) or no nephropathy (n = 191) for 10 years, the presence of CAN (as measured by decreased heart rate variability) in the patients with nephropathy was an independent risk factor for cardiovascular morbidity and mortality [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obstructive sleep apnea
         </strong>
         – Sleep apnea is common among patients with DAN [
         <a href="#rid108">
          108
         </a>
         ]. The severity of DAN among patients with obstructive sleep apnea (OSA) correlates with desaturation rates and the risk of respiratory arrest, contributing to an increased mortality risk [
         <a href="#rid109">
          109-112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H291875198">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116787.html" rel="external">
          "Society guideline links: Neuropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23022003">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15648.html" rel="external">
          "Patient education: Nerve damage caused by diabetes (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1746.html" rel="external">
          "Patient education: Diabetic neuropathy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H173511014">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – DAN is a common form of neuropathy in patients with diabetes mellitus characterized by dysfunction due to impairment of peripheral autonomic nerves. A wide spectrum of manifestations can affect many different organ systems, including the cardiovascular, gastrointestinal, genitourinary, sudomotor and vasomotor, and neuroendocrine systems  (
         <a class="graphic graphic_table graphicRef79376" href="/z/d/graphic/79376.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening
         </strong>
         – We assess all patients with diabetes mellitus for DAN, typically at the time of diagnosis for patients with type 2 diabetes and five years after the diagnosis for patients with type 1 diabetes, as well as annually thereafter for all patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management overview
         </strong>
         – DAN represents a complication of diabetes mellitus. Management to help prevent the development or progression of DAN involves (see
         <a class="local">
          'Overview of management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Optimizing glycemic control
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treating comorbid vascular risk factors (eg, hypertension, hyperlipidemia, obesity)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Addressing specific autonomic symptoms to provide symptomatic relief and reduce associated morbidity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific recommendations for optimized glycemic control and treating comorbid vascular risk factors (eg, hypertension, hyperlipidemia, and obesity) are provided separately.
         <em>
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">
          "Glycemic control and vascular complications in type 1 diabetes mellitus", section on 'Glycemic targets'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">
          "Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiovascular autonomic neuropathy
         </strong>
         – Cardiovascular autonomic neuropathy (CAN) is defined as the impairment of autonomic control of the cardiovascular system. It may be associated with resting tachycardia, exercise intolerance, orthostatic hypotension, and syncope. It is also associated with elevated risks of myocardial ischemia, kidney disease, and ischemic stroke. (See
         <a class="local">
          'Cardiovascular autonomic neuropathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         CAN is diagnosed by cardiovascular reflex testing  (
         <a class="graphic graphic_table graphicRef66386" href="/z/d/graphic/66386.html" rel="external">
          table 4
         </a>
         ). Management involves glycemic control and risk factor management as well as symptomatic strategies to alleviate symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Peripheral autonomic neuropathy
         </strong>
         – Peripheral sudomotor and vasomotor dysfunction leads to thermoregulatory impairment, hyperthermia, and changes in the texture of the skin and/or underlying tissue and joints. Advanced features include chronic peripheral edema, neuroarthropathy, and skin ulceration. The clinical diagnosis of peripheral autonomic neuropathy may be confirmed with superficial recording modalities that identify sudomotor or vasomotor dysfunction. Treatment is supportive. (See
         <a class="local">
          'Peripheral sudomotor and vasomotor neuropathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gastrointestinal autonomic neuropathy
         </strong>
         – DAN that involves autonomic fibers of the enteric nervous system may cause upper and lower gastrointestinal symptoms such as gastroesophageal reflux disease, gastroparesis, and diarrhea. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2643.html" rel="external">
          "Diabetic autonomic neuropathy of the gastrointestinal tract"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Genitourinary autonomic neuropathy
         </strong>
         – Diabetic genitourinary autonomic neuropathy is responsible for several syndromes including bladder dysfunction, retrograde ejaculation, erectile dysfunction, and dyspareunia. (See
         <a class="local">
          'Genitourinary autonomic neuropathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Five-year mortality rates for patients with DAN range between 16 and 53 percent, mostly due to CAN-related complications. Comorbid risk factors associated with poor prognosis in DAN include atherosclerotic heart disease, chronic kidney disease, and obstructive sleep apnea. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H522151749">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Martin Stevens, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Vinik AI, Freeman R, Erbas T. Diabetic autonomic neuropathy. Semin Neurol 2003; 23:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempler P, Tesfaye S, Chaturvedi N, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002; 19:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014; 5:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSayed NA, Aleppo G, Aroda VR, et al. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015; 138:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons CH. Treatment induced neuropathy of diabetes. Auton Neurosci 2020; 226:102668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chantelau E, Meyer-Schwickerath R. Reversion of 'early worsening' of diabetic retinopathy by deliberate restoration of poor metabolic control. Ophthalmologica 2003; 217:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis MD, Beck RW, Home PD, et al. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes 2007; 115:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chantelau E, Meyer-Schwickerath R, Klabe K. Downregulation of serum IGF-1 for treatment of early worsening of diabetic retinopathy: a long-term follow-up of two cases. Ophthalmologica 2010; 224:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pop-Busui R, Low PA, Waberski BH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119:2886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59:2298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons CH, Freeman R, Tecilazich F, et al. The evolving natural history of neurophysiologic function in patients with well-controlled diabetes. J Peripher Nerv Syst 2013; 18:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33:2285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen ST, Witte DR, Fleischer J, et al. Risk Factors for the Presence and Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: ADDITION-Denmark. Diabetes Care 2018; 41:2586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinik AI, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol 2013; 117:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman R. Diabetic autonomic neuropathy. Handb Clin Neurol 2014; 126:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zander E, Schulz B, Heinke P, et al. Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy. Diabetes Care 1989; 12:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011; 161:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page MM, Watkins PJ. Provocation of postural hypotension by insulin in diabetic autonomic neuropathy. Diabetes 1976; 25:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathias CJ, da Costa DF, Fosbraey P, et al. Hypotensive and sedative effects of insulin in autonomic failure. Br Med J (Clin Res Ed) 1987; 295:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornung RS, Mahler RF, Raftery EB. Ambulatory blood pressure and heart rate in diabetic patients: an assessment of autonomic function. Diabet Med 1989; 6:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Istenes I, Keresztes K, Hermányi Z, et al. Relationship between autonomic neuropathy and hypertension--are we underestimating the problem? Diabet Med 2008; 25:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens MJ, Edmonds ME, Mathias CJ, Watkins PJ. Disabling postural hypotension complicating diabetic autonomic neuropathy. Diabet Med 1991; 8:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 1995; 122:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathias CJ. Effect of food intake on cardiovascular control in patients with impaired autonomic function. J Neurosci Methods 1990; 34:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaspar L, Kruzliak P, Komornikova A, et al. Orthostatic hypotension in diabetic patients-10-year follow-up study. J Diabetes Complications 2016; 30:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleg JL, Evans GW, Margolis KL, et al. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension 2016; 68:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension: A 10-year follow-up study. Neurology 2015; 85:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001; 24:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsén A, Kangro M, Sterner G, et al. A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy. Diabet Med 2004; 21:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brotman DJ, Bash LD, Qayyum R, et al. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol 2010; 21:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen JA, Estacio RO, Lundgren RA, et al. Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci 2003; 108:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26:1895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27:2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valensi P, Pariès J, Attali JR, French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications--the French multicenter study. Metabolism 2003; 52:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witte DR, Tesfaye S, Chaturvedi N, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005; 48:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernardi L, Spallone V, Stevens M, et al. Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes Metab Res Rev 2011; 27:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Policy Department, American Association of Neuromuscular &amp; Electrodiagnostic Medicine, Rochester, Minnesota, USA. Proper performance of autonomic function testing. Muscle Nerve 2017; 55:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allman KC, Stevens MJ, Wieland DM, et al. Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1993; 22:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mäntysaari M, Kuikka J, Mustonen J, et al. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine. Diabetes 1992; 41:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreiner G, Wolzt M, Fasching P, et al. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 1995; 44:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995; 25:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wieling W, Borst C, van Dongen Torman MA, et al. Relationship between impaired parasympathetic and sympathetic cardiovascular control in diabetes mellitus. Diabetologia 1983; 24:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004; 44:2368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wieland DM, Hutchins GD, Rosenspire K, et al. C-11 hydroxyephedrine (HED): a high specific activity alternative to F-18 fluorometaraminol (FMR) for heart neuronal imaging. J Nucl Med 1989; 30:A767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melon PG, Nguyen N, DeGrado TR, et al. Imaging of cardiac neuronal function after cocaine exposure using carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1994; 23:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakajo M, Shimabukuro K, Yoshimura H, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986; 27:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwaiger M, Kalff V, Rosenspire K, et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990; 82:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howorka K, Pumprla J, Haber P, et al. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res 1997; 34:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagkalos M, Koutlianos N, Kouidi E, et al. Heart rate variability modifications following exercise training in type 2 diabetic patients with definite cardiac autonomic neuropathy. Br J Sports Med 2008; 42:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller-Stich BP, Billeter AT, Fleming T, et al. Nitrosative stress but not glycemic parameters correlate with improved neuropathy in nonseverely obese diabetic patients after Roux-Y gastric bypass. Surg Obes Relat Dis 2015; 11:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ten Harkel AD, van Lieshout JJ, Wieling W. Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin Sci (Lond) 1994; 87:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkins RW, Kolb LC. Vasomotor disturbance in peripheral neuritis. Am J Med Sci 1941; 202:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fealey RD, Low PA, Thomas JE. Thermoregulatory sweating abnormalities in diabetes mellitus. Mayo Clin Proc 1989; 64:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryder RE, Kennedy RL, Newrick PG, et al. Autonomic denervation may be a prerequisite of diabetic neuropathic foot ulceration. Diabet Med 1990; 7:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tentolouris N, Marinou K, Kokotis P, et al. Sudomotor dysfunction is associated with foot ulceration in diabetes. Diabet Med 2009; 26:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman R, Chapleau MW. Testing the autonomic nervous system. Handb Clin Neurol 2013; 115:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahani BT, Halperin JJ, Boulu P, Cohen J. Sympathetic skin response--a method of assessing unmyelinated axon dysfunction in peripheral neuropathies. J Neurol Neurosurg Psychiatry 1984; 47:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens MJ, Edmonds ME, Douglas SL, Watkins PJ. Influence of neuropathy on the microvascular response to local heating in the human diabetic foot. Clin Sci (Lond) 1991; 80:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2010; 15:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo KR, Chao CC, Chen YT, et al. Quantitation of sudomotor innervation in skin biopsies of patients with diabetic neuropathy. J Neuropathol Exp Neurol 2011; 70:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons CH, Illigens BM, Wang N, Freeman R. Quantification of sweat gland innervation: a clinical-pathologic correlation. Neurology 2009; 72:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007; 56:2148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempler P, Amarenco G, Freeman R, et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes Metab Res Rev 2011; 27:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioanid CP, Noica N, Pop T. Incidence and diagnostic aspects of the bladder disorders in diabetics. Eur Urol 1981; 7:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JS, Wessells H, Chancellor MB, et al. Urologic complications of diabetes. Diabetes Care 2005; 28:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Den Eeden SK, Sarma AV, Rutledge BN, et al. Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care 2009; 32:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarma AV, Kanaya A, Nyberg LM, et al. Risk factors for urinary incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study. Urology 2009; 73:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives. Diabetes Metab Syndr Obes 2014; 7:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giraldi A, Kristensen E. Sexual dysfunction in women with diabetes mellitus. J Sex Res 2010; 47:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: a systematic review and meta-analysis. J Sex Med 2013; 10:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan D, Spaeth EB, Vernino S, Muppidi S. Disproportionate pupillary involvement in diabetic autonomic neuropathy. Clin Auton Res 2014; 24:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amiel S. Glucose counter-regulation in health and disease: current concepts in hypoglycaemia recognition and response. Q J Med 1991; 80:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cryer PE. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle. Diabetes 1992; 41:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer C, Grossmann R, Mitrakou A, et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1998; 21:1960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YK, Fisher SJ, Pop-Busui R. Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies. J Diabetes Investig 2020; 11:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991; 79:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro X, Kennedy WR, Sutherland DE. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia 1991; 34 Suppl 1:S108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rathmann W, Ziegler D, Jahnke M, et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993; 10:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson MJ, Wilson S, Karagiannis P, et al. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med 1990; 75:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980; 49:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watkins PJ, Mackay JD. Cardiac denervation in diabetic neuropathy. Ann Intern Med 1980; 92:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegler D. Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Reviews 1999; 7:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988; 108:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambepityia G, Kopelman PG, Ingram D, et al. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990; 15:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer A, Freeman MR, Josse RG, et al. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 1991; 67:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewing DJ, Campbell IW, Clarke BF. Mortality in diabetic autonomic neuropathy. Lancet 1976; 1:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgos LG, Ebert TJ, Asiddao C, et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989; 70:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veglio M, Sivieri R, Chinaglia A, et al. QT interval prolongation and mortality in type 1 diabetic patients: a 5-year cohort prospective study. Neuropathy Study Group of the Italian Society of the Study of Diabetes, Piemonte Affiliate. Diabetes Care 2000; 23:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lown B, Verrier RL, Rabinowitz SH. Neural and psychologic mechanisms and the problem of sudden cardiac death. Am J Cardiol 1977; 39:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998; 98:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez GA, Clark VM, Norell JE, et al. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry 2005; 76:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Astrup AS, Tarnow L, Rossing P, et al. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006; 29:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottini P, Redolfi S, Dottorini ML, Tantucci C. Autonomic neuropathy increases the risk of obstructive sleep apnea in obese diabetics. Respiration 2008; 75:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page MM, Watkins PJ. Cardiorespiratory arrest and diabetic autonomic neuropathy. Lancet 1978; 1:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees PJ, Prior JG, Cochrane GM, Clark TJ. Sleep apnoea in diabetic patients with autonomic neuropathy. J R Soc Med 1981; 74:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ficker JH, Dertinger SH, Siegfried W, et al. Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. Eur Respir J 1998; 11:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann C, Martinez D, Schmid H. Nocturnal oxygen desaturation in diabetic patients with severe autonomic neuropathy. Diabetes Res Clin Pract 1995; 28:97.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5285 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15088257" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12421426" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24567799" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cardiac autonomic neuropathy in patients with diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15793206" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diabetic neuropathies: a statement by the American Diabetes Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507636" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25392197" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32247944" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment induced neuropathy of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9682700" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12913330" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Reversion of 'early worsening' of diabetic retinopathy by deliberate restoration of poor metabolic control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17479440" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19940532" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Downregulation of serum IGF-1 for treatment of early worsening of diabetic retinopathy: a long-term follow-up of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9562345" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19470886" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12556541" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256393" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of a multifactorial intervention on mortality in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18539917" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effects of intensive glucose lowering in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27531506" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15673800" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Vascular risk factors and diabetic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16644706" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23781962" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The evolving natural history of neurophysiologic function in patients with well-controlled diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12716821" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876709" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30305347" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risk Factors for the Presence and Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: ADDITION-Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24095132" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25410215" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2707113" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21393070" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/942932" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Provocation of postural hypotension by insulin in diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3115360" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hypotensive and sedative effects of insulin in autonomic failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2527697" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ambulatory blood pressure and heart rate in diabetic patients: an assessment of autonomic function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18513306" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Relationship between autonomic neuropathy and hypertension--are we underestimating the problem?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1837515" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Disabling postural hypotension complicating diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7825766" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Postprandial hypotension: epidemiology, pathophysiology, and clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1979648" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of food intake on cardiovascular control in patients with impaired autonomic function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26412028" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Orthostatic hypotension in diabetic patients-10-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27504006" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26400576" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical implications of delayed orthostatic hypotension: A 10-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15277423" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11213889" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15270788" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20616169" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Heart rate variability predicts ESRD and CKD-related hospitalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14614967" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Diabetic autonomic neuropathy is associated with an increased incidence of strokes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12766130" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21695768" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15562211" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Autonomic symptoms and diabetic neuropathy: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12870154" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications--the French multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15619072" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21695761" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Methods of investigation for cardiac autonomic dysfunction in human research studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27786371" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Proper performance of autonomic function testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8227801" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1499860" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7729613" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7860904" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6884607" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Relationship between impaired parasympathetic and sympathetic cardiovascular control in diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15607400" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : C-11 hydroxyephedrine (HED): a high specific activity alternative to F-18 fluorometaraminol (FMR) for heart neuronal imaging
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8195534" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Imaging of cardiac neuronal function after cocaine exposure using carbon-11 hydroxyephedrine and positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3941369" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2372893" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9217892" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17526623" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Heart rate variability modifications following exercise training in type 2 diabetic patients with definite cardiac autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25862183" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Nitrosative stress but not glycemic parameters correlate with improved neuropathy in nonseverely obese diabetic patients after Roux-Y gastric bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7874844" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28050656" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Vasomotor disturbance in peripheral neuritis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2747292" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Thermoregulatory sweating abnormalities in diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2147635" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Autonomic denervation may be a prerequisite of diabetic neuropathic foot ulceration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19317826" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Sudomotor dysfunction is associated with foot ulceration in diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23931777" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Testing the autonomic nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6330307" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Sympathetic skin response--a method of assessing unmyelinated axon dysfunction in peripheral neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1850685" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Influence of neuropathy on the microvascular response to local heating in the human diabetic foot.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20626771" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21937916" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Quantitation of sudomotor innervation in skin biopsies of patients with diabetic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19398703" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Quantification of sweat gland innervation: a clinical-pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17513704" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Surrogate markers of small fiber damage in human diabetic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21748841" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7227400" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Incidence and diagnostic aspects of the bladder disorders in diabetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15616253" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Urologic complications of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19171725" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19362350" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Risk factors for urinary incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24623985" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Diabetes and sexual dysfunction: current perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20358461" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Sexual dysfunction in women with diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19181643" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A population-based, longitudinal study of erectile dysfunction and future coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23347454" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Female sexual dysfunction and diabetes: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25377131" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Disproportionate pupillary involvement in diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1754672" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Glucose counter-regulation in health and disease: current concepts in hypoglycaemia recognition and response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8450063" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1551485" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802751" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32403204" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1946930" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The influence of autonomic neuropathy on mortality in insulin-dependent diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1936671" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8281726" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Mortality in diabetic patients with cardiovascular autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2217668" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7433630" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The natural history of diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7356218" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Cardiac denervation in diabetic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Cardiovascular autonomic neuropathy: clinical manifestations and measurement
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3341650" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2295745" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2024596" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Detection of silent myocardial ischemia in diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/55889" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Mortality in diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2929996" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10977037" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : QT interval prolongation and mortality in type 1 diabetic patients: a 5-year cohort prospective study. Neuropathy Study Group of the Italian Society of the Study of Diabetes, Piemonte Affiliate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/860697" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Neural and psychologic mechanisms and the problem of sudden cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9737515" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15654040" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16443883" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17347559" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Autonomic neuropathy increases the risk of obstructive sleep apnea in obese diabetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/74496" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Cardiorespiratory arrest and diabetic autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7205856" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Sleep apnoea in diabetic patients with autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9543264" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7587925" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Nocturnal oxygen desaturation in diabetic patients with severe autonomic neuropathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
